Is Quince Therapeutics Inc (NASDAQ:QNCX) Worth A Patient Look At Current Prices?

Quince Therapeutics Inc (NASDAQ:QNCX)’s traded shares stood at 1.01 million during the last session, with the company’s beta value hitting 0.71. At the close of trading, the stock’s price was $1.78, to imply a decrease of -6.32% or -$0.12 in intraday trading. The QNCX share’s 52-week high remains $1.95, putting it -9.55% down since that peak but still an impressive 71.35% since price per share fell to its 52-week low of $0.51. The company has a valuation of $78.32M, with an average of 0.36 million shares in intraday trading volume over the past 10 days and average of 554.80K shares over the past 3 months.

Quince Therapeutics Inc (NASDAQ:QNCX) trade information

After registering a -6.32% downside in the last session, Quince Therapeutics Inc (QNCX) has traded red over the past five days. The 5-day price performance for the stock is 4.71%, and 124.49% over 30 days. With these gigs, the year-to-date price performance is 69.52%. Short interest in Quince Therapeutics Inc (NASDAQ:QNCX) saw shorts transact 2.35 million shares and set a 2.27 days time to cover.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

QNCX Dividends

Quince Therapeutics Inc has its next earnings report out on 2024-Nov-13. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

Quince Therapeutics Inc (NASDAQ:QNCX)’s Major holders

Quince Therapeutics Inc insiders hold 13.74% of total outstanding shares, with institutional holders owning 25.53% of the shares at 29.60% float percentage. In total, 25.53% institutions holds shares in the company.